Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Jamilya Kh KhizroevaViktoriya O BitsadzeAngela TincaniAlexander MakatsaryaMadina ArslanbekovaNigar BabaevaValentina I TsibizovaAndrei ShkodaNatalya MakatsariyaMaria TretyakovaAntonina SolopovaZumrad GadaevaAlexander VorobevInessa KhamaniZamilya AslanovaInga NakaidzeAlexander MischenkoKristina GrigorevaNart KuneskoElena EgorovaTamara MashkovaPublished in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2021)
In 20-30% of cases the live birth despite anticoagulation cannot be achieved. Perhaps APS is not just anticoagulation. The study of pathophysiological mechanisms suggests that some patients will benefit from other therapy (in addition to anticoagulant). Therapy that affects the early effects of aPL on target cells (monocytes, endothelial cells, etc.) or before binding to receptors-this therapy will be preferable and potentially less harmful than the officially accepted one to date. From this point of view, HCQ looks promising and can be used as an alternative candidate for women with refractory obstetric antiphospholipid syndrome. Adding HCQ should be considered in some selected patients with failed pregnancy after treatment with anticoagulants.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- endothelial cells
- pregnant women
- end stage renal disease
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- clinical trial
- preterm birth
- mesenchymal stem cells
- cell therapy
- signaling pathway
- cell cycle arrest
- cell proliferation
- peritoneal dialysis
- patient reported outcomes
- patient reported
- gestational age